Omnicell (OMCL) Projected to Post Earnings on Tuesday

Omnicell (NASDAQ:OMCL) is projected to release its Q1 2025 earnings data before the market opens on Tuesday, May 6th. Analysts expect the company to announce earnings of $0.16 per share and revenue of $260.18 million for the quarter. Omnicell has set its Q1 2025 guidance at 0.150-0.250 EPS and its FY 2025 guidance at 1.650-1.850 EPS.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings data on Thursday, February 6th. The company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.57 by ($0.12). Omnicell had a net margin of 1.13% and a return on equity of 3.82%. On average, analysts expect Omnicell to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Omnicell Trading Down 0.7 %

NASDAQ OMCL opened at $31.16 on Friday. Omnicell has a 1 year low of $25.12 and a 1 year high of $55.75. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.37 and a quick ratio of 1.22. The company has a market capitalization of $1.46 billion, a PE ratio of 115.41, a P/E/G ratio of 7.53 and a beta of 0.78. The company has a fifty day moving average of $33.47 and a 200 day moving average of $40.46.

Analyst Ratings Changes

Several research analysts recently weighed in on the company. Benchmark reiterated a “buy” rating and set a $62.00 price target on shares of Omnicell in a research report on Tuesday, February 4th. Wells Fargo & Company decreased their target price on shares of Omnicell from $40.00 to $38.00 and set an “equal weight” rating for the company in a research note on Thursday, April 17th. StockNews.com lowered shares of Omnicell from a “buy” rating to a “hold” rating in a research report on Saturday. Bank of America decreased their price objective on shares of Omnicell from $54.00 to $46.00 and set a “neutral” rating for the company in a research report on Monday, January 6th. Finally, JPMorgan Chase & Co. dropped their target price on Omnicell from $44.00 to $36.00 and set a “neutral” rating on the stock in a research report on Thursday, March 20th. Five research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, Omnicell has an average rating of “Hold” and an average target price of $50.67.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.